| IGA Glomerulonephritis
Fabhalta vs Filspari
Side-by-side clinical, coverage, and cost comparison for iga glomerulonephritis.Deep comparison between: Fabhalta vs Filspari with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFilspari has a higher rate of injection site reactions vs Fabhalta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Filspari but not Fabhalta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fabhalta
Filspari
At A Glance
Oral
Twice daily
Factor B inhibitor
Oral
Daily
Endothelin/angiotensin II receptor antagonist
Indications
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
- IGA Glomerulonephritis
- Focal glomerulosclerosis
Dosing
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
IGA Glomerulonephritis Initiate at 200 mg orally once daily; after 14 days, increase to 400 mg once daily as tolerated.
Focal glomerulosclerosis Adults and pediatric patients >=8 years weighing >50 kg: initiate at 400 mg orally once daily, increase to 800 mg once daily after 14 days as tolerated; weighing <=50 kg: initiate at 200 mg orally once daily, increase to 400 mg once daily after 14 days as tolerated.
Contraindications
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
- Pregnancy
- Co-administration with angiotensin receptor blockers (ARBs), endothelin receptor antagonists (ERAs), or aliskiren
Adverse Reactions
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Most common (>=2%) Peripheral edema, hypotension (including orthostatic hypotension), hyperkalemia, dizziness, anemia, acute kidney injury, transaminase elevations
Serious Hepatotoxicity, embryo-fetal toxicity, hypotension, acute kidney injury, hyperkalemia, fluid retention
Pharmacology
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Sparsentan is a single molecule with antagonism of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R); it has high affinity for both receptors and blocks ET-1 and angiotensin II signaling pathways thought to be involved in the pathogenesis of IgAN and FSGS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Filspari
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Filspari
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Filspari
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FabhaltaView full Fabhalta profile
FilspariView full Filspari profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.